Difference between revisions of "Template:Immunohistochemistry evaluation of invasive breast cancer"
Jump to navigation
Jump to search
(→Immunohistochemistry: Expand) |
(→Immunohistochemistry: Formatting) |
||
| Line 1: | Line 1: | ||
===Immunohistochemistry=== | ===Immunohistochemistry=== | ||
*'''Ki-67''' index:<ref name="DowsettNielsen2011">{{cite journal|last1=Dowsett|first1=M.|last2=Nielsen|first2=T. O.|last3=A'Hern|first3=R.|last4=Bartlett|first4=J.|last5=Coombes|first5=R. C.|last6=Cuzick|first6=J.|last7=Ellis|first7=M.|last8=Henry|first8=N. L.|last9=Hugh|first9=J. C.|last10=Lively|first10=T.|last11=McShane|first11=L.|last12=Paik|first12=S.|last13=Penault-Llorca|first13=F.|last14=Prudkin|first14=L.|last15=Regan|first15=M.|last16=Salter|first16=J.|last17=Sotiriou|first17=C.|last18=Smith|first18=I. E.|last19=Viale|first19=G.|last20=Zujewski|first20=J. A.|last21=Hayes|first21=D. F.|title=Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group|journal=JNCI Journal of the National Cancer Institute|volume=103|issue=22|year=2011|pages=1656–1664|issn=0027-8874|doi=10.1093/jnci/djr393}}</ref> | *'''Ki-67''' index:<ref name="DowsettNielsen2011">{{cite journal|last1=Dowsett|first1=M.|last2=Nielsen|first2=T. O.|last3=A'Hern|first3=R.|last4=Bartlett|first4=J.|last5=Coombes|first5=R. C.|last6=Cuzick|first6=J.|last7=Ellis|first7=M.|last8=Henry|first8=N. L.|last9=Hugh|first9=J. C.|last10=Lively|first10=T.|last11=McShane|first11=L.|last12=Paik|first12=S.|last13=Penault-Llorca|first13=F.|last14=Prudkin|first14=L.|last15=Regan|first15=M.|last16=Salter|first16=J.|last17=Sotiriou|first17=C.|last18=Smith|first18=I. E.|last19=Viale|first19=G.|last20=Zujewski|first20=J. A.|last21=Hayes|first21=D. F.|title=Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group|journal=JNCI Journal of the National Cancer Institute|volume=103|issue=22|year=2011|pages=1656–1664|issn=0027-8874|doi=10.1093/jnci/djr393}}</ref> | ||
| − | + | [[File:Positive immunohistochemistry of KI-67 in invasive breast cancer.jpg|thumb|Ki-67 in an invasive breast cancer: cancer nuclei are stained (brown). There is tumor cell positivity in 70% of the cells (''Ki-67 labelling index'' = 70%).]] | |
| − | File:Positive immunohistochemistry of KI-67 in invasive breast cancer.jpg|Ki-67 in an invasive breast cancer: cancer nuclei are stained (brown). There is tumor cell positivity in 70% of the cells (''Ki-67 labelling index'' = 70%) | ||
| − | |||
| − | |||
:*At least three high-power (×40 objective) fields should be selected | :*At least three high-power (×40 objective) fields should be selected | ||
:*At least 500 malignant invasive cells should be counted, unless a protocol clearly states reasons for fewer being acceptable. | :*At least 500 malignant invasive cells should be counted, unless a protocol clearly states reasons for fewer being acceptable. | ||
| Line 10: | Line 7: | ||
:*If a comparisons must be made between core biopsies and sections from an excision, evaluation of the latter should be across the whole tumor. | :*If a comparisons must be made between core biopsies and sections from an excision, evaluation of the latter should be across the whole tumor. | ||
:*Only nuclear staining counts. Staining intensity of a positive nucleus is not relevant. | :*Only nuclear staining counts. Staining intensity of a positive nucleus is not relevant. | ||
| − | |||
*'''HER2/neu''' score or status: | *'''HER2/neu''' score or status: | ||
{|class="wikitable" align="right" | {|class="wikitable" align="right" | ||
| Line 20: | Line 16: | ||
|- | |- | ||
| 3+ || HER2 positive | | 3+ || HER2 positive | ||
| − | |}<noinclude> | + | |} |
| + | <gallery mode=packed heights=200> | ||
| + | File:Positive immunohistochemistry of HER2 in invasive breast cancer.jpg|HER2/neu staining is seen as a cell membrane with continuous brown color. | ||
| + | </gallery> | ||
| + | <noinclude> | ||
{{Bottom}} | {{Bottom}} | ||
</noinclude> | </noinclude> | ||
Revision as of 12:09, 28 September 2020
Immunohistochemistry
- Ki-67 index:[1]
- At least three high-power (×40 objective) fields should be selected
- At least 500 malignant invasive cells should be counted, unless a protocol clearly states reasons for fewer being acceptable.
- The invasive edge of the tumor should be scored
- If a comparisons must be made between core biopsies and sections from an excision, evaluation of the latter should be across the whole tumor.
- Only nuclear staining counts. Staining intensity of a positive nucleus is not relevant.
- HER2/neu score or status:
| Score[2] | Status[2] |
|---|---|
| 0 to 1+ | HER2 negative (not present) |
| 2+ | Borderline |
| 3+ | HER2 positive |
HER2/neu staining is seen as a cell membrane with continuous brown color.
Notes
Main page
References
- ↑ Dowsett, M.; Nielsen, T. O.; A'Hern, R.; Bartlett, J.; Coombes, R. C.; Cuzick, J.; Ellis, M.; Henry, N. L.; et al. (2011). "Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group ". JNCI Journal of the National Cancer Institute 103 (22): 1656–1664. doi:. ISSN 0027-8874.
- ↑ 2.0 2.1 . IHC Tests (ImmunoHistoChemistry). Breastcancer.org. Retrieved on 2019-10-04. Last modified on October 23, 2015
Image sources
